Biodesix, Inc. (BDSX) vs Lyell Immunopharma, Inc. (LYEL)

A side-by-side comparison of Biodesix, Inc. and Lyell Immunopharma, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — BDSX vs LYEL

growth of $100 · dividends reinvested · last 5y
BDSX -90.1% (-37.1%/yr)LYEL -97.3% (-51.5%/yr)BDSX compounded faster over this window
020406080100Start $10020222023202420252026$10$3
BDSX LYEL

BDSX vs LYEL: by the numbers

  • •BDSX is the larger company ($232M vs $214M market cap).
  • •Both run net losses; BDSX's is the smaller (-26.97% vs -920285.19% net margin).
  • •BDSX grew revenue faster over the past five years (5.99% vs -68.32% CAGR).

Metrics side by side

Valuation

MetricBDSXLYEL
P/S ratio2.257932.15
P/B ratio25.340.92

Profitability

MetricBDSXLYEL
Gross margin82.50%-31952.78%
Operating margin-31.37%-566038.89%
Net margin-26.97%-920285.19%
ROE-303.61%-106.27%
ROIC-25.73%-70.80%

Growth (annualized)

MetricBDSXLYEL
Revenue CAGR (5Y)5.99%-68.32%
Total return CAGR (5Y)-28.49%-48.18%

Frequently asked

Which has grown faster, BDSX or LYEL?
Over the past five years, BDSX grew revenue faster — BDSX at a 5.99% CAGR versus LYEL at -68.32%.
How have BDSX and LYEL total returns compared?
Over the past 5 years, BDSX delivered -28.49% and LYEL delivered -48.18% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.